These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 17952066)

  • 81. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Substrate specificity of heparanases from human hepatoma and platelets.
    Pikas DS; Li JP; Vlodavsky I; Lindahl U
    J Biol Chem; 1998 Jul; 273(30):18770-7. PubMed ID: 9668050
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Heparan sulfate and heparanase as modulators of breast cancer progression.
    Gomes AM; Stelling MP; Pavão MS
    Biomed Res Int; 2013; 2013():852093. PubMed ID: 23984412
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase.
    Lai NS; Simizu S; Morisaki D; Muroi M; Osada H
    Exp Cell Res; 2008 Sep; 314(15):2834-45. PubMed ID: 18662687
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A conformational change in heparan sulfate 3-O-sulfotransferase-1 is induced by binding to heparan sulfate.
    Edavettal SC; Carrick K; Shah RR; Pedersen LC; Tropsha A; Pope RM; Liu J
    Biochemistry; 2004 Apr; 43(16):4680-8. PubMed ID: 15096036
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Molecular properties and involvement of heparanase in cancer progression and normal development.
    Vlodavsky I; Goldshmidt O; Zcharia E; Metzger S; Chajek-Shaul T; Atzmon R; Guatta-Rangini Z; Friedmann Y
    Biochimie; 2001 Aug; 83(8):831-9. PubMed ID: 11530216
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Heparan sulfate proteoglycans and cancer.
    Blackhall FH; Merry CL; Davies EJ; Jayson GC
    Br J Cancer; 2001 Oct; 85(8):1094-8. PubMed ID: 11710818
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A defect in exodegradative pathways provides insight into endodegradation of heparan and dermatan sulfates.
    Fuller M; Chau A; Nowak RC; Hopwood JJ; Meikle PJ
    Glycobiology; 2006 Apr; 16(4):318-25. PubMed ID: 16377754
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The role of heparanase in gastrointestinal cancer (Review).
    Naomoto Y; Takaoka M; Okawa T; Nobuhisa T; Gunduz M; Tanaka N
    Oncol Rep; 2005 Jul; 14(1):3-8. PubMed ID: 15944760
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Transgenic over-expression of mammalian heparanase delays prion disease onset and progression.
    Kovalchuk Ben-Zaken O; Nissan I; Tzaban S; Taraboulos A; Zcharia E; Matzger S; Shafat I; Vlodavsky I; Tal Y
    Biochem Biophys Res Commun; 2015 Aug; 464(3):698-704. PubMed ID: 26168721
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Heparanase - Discovery and Targets.
    Lindahl U; Li JP
    Adv Exp Med Biol; 2020; 1221():61-69. PubMed ID: 32274706
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Heparanase Mediates Intestinal Inflammation and Injury in a Mouse Model of Sepsis.
    Chen S; He Y; Hu Z; Lu S; Yin X; Ma X; Lv C; Jin G
    J Histochem Cytochem; 2017 Apr; 65(4):241-249. PubMed ID: 28170292
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Perlecan-rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor.
    Tsuneki M; Cheng J; Maruyama S; Ida-Yonemochi H; Nakajima M; Saku T
    J Oral Pathol Med; 2008 May; 37(5):287-93. PubMed ID: 18205742
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Deciphering mode of action of heparanase using structurally defined oligosaccharides.
    Peterson S; Liu J
    J Biol Chem; 2012 Oct; 287(41):34836-43. PubMed ID: 22893710
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity.
    Zhang Y; Wang N; Raab RW; McKown RL; Irwin JA; Kwon I; van Kuppevelt TH; Laurie GW
    J Biol Chem; 2013 Apr; 288(17):12090-101. PubMed ID: 23504321
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors.
    Hunter KE; Palermo C; Kester JC; Simpson K; Li JP; Tang LH; Klimstra DS; Vlodavsky I; Joyce JA
    Oncogene; 2014 Apr; 33(14):1799-808. PubMed ID: 23644656
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
    Lanzi C; Zaffaroni N; Cassinelli G
    Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Heparan sulfate domain organization and sulfation modulate FGF-induced cell signaling.
    Jastrebova N; Vanwildemeersch M; Lindahl U; Spillmann D
    J Biol Chem; 2010 Aug; 285(35):26842-26851. PubMed ID: 20576609
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Insights into the role of heparan sulphate in fibroblast growth factor signalling.
    Harmer NJ
    Biochem Soc Trans; 2006 Jun; 34(Pt 3):442-5. PubMed ID: 16709182
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.
    Gingis-Velitski S; Zetser A; Kaplan V; Ben-Zaken O; Cohen E; Levy-Adam F; Bashenko Y; Flugelman MY; Vlodavsky I; Ilan N
    J Biol Chem; 2004 Oct; 279(42):44084-92. PubMed ID: 15292202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.